151
Participants
Start Date
September 30, 2014
Primary Completion Date
September 30, 2017
Study Completion Date
November 30, 2017
Rituximab
"Induction with two infusions two weeks apart, rituximab 500 mg/m2 (max 1000 mg).~Maintenance with rituximab infusions (500 mg fixed dose) at 3, 6, 9 and 12 months."
Placebo
Saline (NaCl 0,9%) added human albumin (Flexbumin) 0,4 mg/ml, two infusions two weeks apart. Maintenance infusions after 3,6, 9 and 12 months.
Dept. of Oncology, Haukeland University Hospital, Bergen
Notodden Hospital, Notodden
CFS/ME centre, Oslo University Hospital, Oslo
Division of Rehabilitation Services, University Hospital of North Norway, Tromsø
Dept. of Pain and Complex Disorders, St. Olavs Hospital, Trondheim
The Research Council of Norway
OTHER
Norwegian Department of Health and Social Affairs
OTHER_GOV
The Kavli Foundation
UNKNOWN
Oslo University Hospital
OTHER
Trondheim University Hospital
OTHER
University Hospital of North Norway
OTHER
Sykehuset Telemark
OTHER_GOV
MEandYou Foundation
UNKNOWN
The Norwegian ME association
UNKNOWN
Haukeland University Hospital
OTHER